ELITE PHARMACEUTICALS INC /NV/ 8-K

What Happened
Elite Pharmaceuticals, Inc. (ELTP) announced on June 1, 2026 that it filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration for a generic version of an undisclosed drug product in the anticoagulant medication class. The company made the announcement via a press release, which is furnished as Exhibit 99.1 to its Form 8-K (Item 7.01, Regulation FD Disclosure).

Key Details

• Filed an ANDA with the FDA on June 1, 2026.
• Product class: anticoagulants; the specific reference product is not disclosed in the filing.
• Disclosure method: press release included as Exhibit 99.1 to the Form 8-K.
• The Form 8-K did not include financial statements or additional material financial updates.

Why It Matters
Filing an ANDA is a formal step toward obtaining FDA approval to market a generic version of an approved drug. If the FDA grants approval, Elite would be authorized to sell that generic product, which could affect future product sales and revenue; however, the filing itself is not an approval and the company provided no timelines, financial estimates, or guarantees in this filing. Investors should note this is a disclosure under Regulation FD and monitor future updates from Elite and the FDA for information on review progress, approval decisions, or commercial plans.